Did Novo Nordisk Just Say "Checkmate" to Pfizer?

Novo Nordisk's (NYSE: NVO) shares have dropped significantly over the past year, partly due to clinical setbacks in its core GLP-1 portfolio. However, the Denmark-based pharmaceutical leader has been trying to turn things around. The company has expanded its pipeline through internal innovation and astute acquisitions.The latest buyout Novo Nordisk is trying to pull off is putting it in a direct confrontation with another beaten-down pharmaceutical giant: Pfizer (NYSE: PFE). Let's see what's happening between these two, and what it means for investors.Image source: Getty Images.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool